Streetbeat News

NAUT

Nautilus Biotechnology, Inc.

https://www.nautilus.bio

Industry

Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Nautilus Biotechnology (NASDAQ:NAUT) reported a Q2 EPS of $(0.14), beating the analyst estimate of $(0.16) by 12.5%. This represents a 7.69% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 10:09 am

Nautilus Biotechnology shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 3:58 pm

Guggenheim has initiated coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and set a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 11:09 am

Jefferies analyst Tycho Peterson has assumed coverage of Nautilus Biotechnology (NASDAQ:NAUT) with a Hold rating and has lowered the price target to $3.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 6:16 pm

Nautilus Biotechnology's stock price increased following the announcement of their Q1 earnings per share (EPS) results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 4:03 pm

Nautilus Biotechnology reported its cash, cash equivalents, and investments totaled $247.7 million as of March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:07 am

Nautilus Biotechnology reported Q1 2024 GAAP EPS of $(0.15), surpassing the $(0.17) estimate, marking an 11.76% beat but a 25% increase in losses from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:06 am

In Friday's pre-market session, several healthcare stocks showed significant movement. Avalo Therapeutics (AVTX) led the gainers with a 289.1% increase, while NuCana (NCNA) led the losers with a 21.9% decrease. Other notable movers include Xilio Therapeutics (XLO) and Biodexa Pharmaceuticals (BDRX) with substantial gains, and PAVmed (PAVM) and BioCardia (BCDA) with notable losses.

Portfolio Pulse from Benzinga Insights

March 29, 2024 | 12:06 pm

Nautilus Biotechnology has entered into a sales agreement with Cowen for the sale of common stock, aiming for aggregate sales proceeds of up to $125 million. This move is part of Nautilus Biotechnology's efforts to raise capital.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:28 pm

Nautilus Biotechnology (NASDAQ:NAUT) reported Q4 2023 GAAP EPS of $(0.14), surpassing the $(0.15) estimate by 6.67%. However, this represents a 27.27% increase in losses compared to $(0.11) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.